To include your compound in the COVID-19 Resource Center, submit it here.

Cilengitide: Completed Phase III enrollment

Merck's EMD Serono Inc. affiliate completed enrollment of >500 newly diagnosed

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE